Original Contribution | Published:

Functional Gi

Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

The American Journal of Gastroenterology volume 101, pages 15811590 (2006) | Download Citation




Probiotic bacteria exhibit a variety of properties, including immunomodulatory activity, which are unique to a particular strain. Thus, not all species will necessarily have the same therapeutic potential in a particular condition. We have preliminary evidence that Bifidobacterium infantis 35624 may have utility in irritable bowel syndrome (IBS).


This study was designed to confirm the efficacy of the probiotic bacteria B. infantis 35624 in a large-scale, multicenter, clinical trial of women with IBS. A second objective of the study was to determine the optimal dosage of probiotic for administration in an encapsulated formulation.


After a 2-wk baseline, 362 primary care IBS patients, with any bowel habit subtype, were randomized to either placebo or freeze-dried, encapsulated B. infantis at a dose of 1 × 106, 1 × 108, or 1 × 1010, cfu/mL for 4 wk. IBS symptoms were monitored daily and scored on to a 6-point Likert scale with the primary outcome variable being abdominal pain or discomfort. A composite symptom score, the subject's global assessment of IBS symptom relief, and measures of quality of life (using the IBS-QOL instrument) were also recorded.


B. infantis 35624 at a dose of 1 × 108 cfu was significantly superior to placebo and all other bifidobacterium doses for the primary efficacy variable of abdominal pain as well as the composite score and scores for bloating, bowel dysfunction, incomplete evacuation, straining, and the passage of gas at the end of the 4-wk study. The improvement in global symptom assessment exceeded placebo by more than 20% (p < 0.02). Two other doses of probiotic (1 × 106 and 1 × 1010) were not significantly different from placebo; of these, the 1 × 1010 dose was associated with significant formulation problems. No significant adverse events were recorded.


B. infantis 35624 is a probiotic that specifically relieves many of the symptoms of IBS. At a dosage level of 1 × 108 cfu, it can be delivered by a capsule making it stable, convenient to administer, and amenable to widespread use. The lack of benefits observed with the other dosage levels of the probiotic highlight the need for clinical data in the final dosage form and dose of probiotic before these products should be used in practice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , . Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652–663.

  2. 2.

    , . Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets 2003;7:343–362.

  3. 3.

    . Corticotropin releasing factor receptor antagonists: Potential future therapy in gastroenterology? Gut 2004;53:919–921.

  4. 4.

    . Serotoninergic neuroenteric modulators. Lancet 2001;358:2061–2068.

  5. 5.

    , , . Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.

  6. 6.

    , , , et al. Tegaserod, a 5-HT receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–1666.

  7. 7.

    . Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662–1671.

  8. 8.

    , , , et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778–1783.

  9. 9.

    , , , et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972–1979.

  10. 10.

    , , , et al. Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an inflammatory component? Gut 2003;52:91–93.

  11. 11.

    , , , et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.

  12. 12.

    . Irritable bowel syndrome and inflammatory bowel disease: Interrelated diseases? Chin J Dig Dis 2005;6:122–132.

  13. 13.

    , , , et al. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002;97:104–108.

  14. 14.

    , , . Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503–3506.

  15. 15.

    , , . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412–419.

  16. 16.

    . The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 2005;34:533–545.

  17. 17.

    , , , et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975–980.

  18. 18.

    , , , et al. Probiotic performance in IBD is not uniform: A multi-strain comparison in the lymphocyte transfer model of enterocolitis. Gastroenterology 2004;126:A283–A284.

  19. 19.

    , , , et al. Mechanism of probiotic/commensal mediated protection against invasive salmonella infection. Gastroenterology 2004;126:A516.

  20. 20.

    . Probiotics in the management of irritable bowel syndrome: A review of clinical trials. Microb Ecol Health Dis 2001;13:212–216.

  21. 21.

    , , , et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–551.

  22. 22.

    , , , et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45:II43–II47.

  23. 23.

    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). American Psychiatric Association: Washington DC, 1994.

  24. 24.

    , , , et al. Defecation frequency and timing, and stool form in the general population: A prospective study. Gut 1992;33:818–824.

  25. 25.

    , , , et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999–1007.

  26. 26.

    , . The hospital anxiety and depression index. Acta Psychiatr Scand 1983;67:361–370.

  27. 27.

    , , , et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator. Gastroenterology 2005;128:580–589.

  28. 28.

    , , , et al. Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmcol Ther 2003;18:569–580.

  29. 29.

    . From comic relief to real understanding; how intestinal gas causes symptoms. Gut 2003;52:1659–1661.

  30. 30.

    , , , et al. Non-colonic features of irritable bowel syndrome. Gut 1986;27:37–40.

  31. 31.

    , , , et al. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil 2005;17:29–34.

  32. 32.

    , , , et al. Nongastrointestinal disorders in the irritable bowel syndrome. Digestion 2000;62:66–72.

  33. 33.

    , , . Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002;122:1140–1156.

  34. 34.

    , , , et al. The prevalence, patterns and impact of irritable bowel syndrome: An international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17:643–650.

  35. 35.

    , , , et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895–904.

  36. 36.

    , , , et al. A randomised controlled trial of probiotic combination VSL#3 and placebo in IBS with bloating. Neurogastroenterol Motil 2005;17:687–696.

  37. 37.

    , , , et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome: A controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387–394.

  38. 38.

    , , , et al. The efficacy of Lactobacillus reuterii ATCC 55740 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. Clin Nutr 2005;24:925–931.

  39. 39.

    , . The use of Lactobacillus GG in irritable bowel syndrome in children: Results of a double-blind randomized control trial. J Pediatr 2005;147:197–201.

Download references

Author information


  1. Department of Medicine, University of Manchester, Manchester, UK

    • Peter J Whorwell
  2. The Procter and Gamble Company, Personal Health Care Division, Mason, Ohio

    • Linda Altringer
    • , Jorge Morel
    •  & Duane Charbonneau
  3. Procter & Gamble, Rusham Park Technical Center, Egham, UK

    • Yvonne Bond
  4. Alimentary Pharmabiotic Center, University College, Cork, Ireland

    • Liam O'Mahony
    • , Fergus Shanahan
    •  & Eamonn M M Quigley
  5. Alimentary Health Ltd, Kinsale, Co Cork, Ireland

    • Barry Kiely


  1. Search for Peter J Whorwell in:

  2. Search for Linda Altringer in:

  3. Search for Jorge Morel in:

  4. Search for Yvonne Bond in:

  5. Search for Duane Charbonneau in:

  6. Search for Liam O'Mahony in:

  7. Search for Barry Kiely in:

  8. Search for Fergus Shanahan in:

  9. Search for Eamonn M M Quigley in:

Corresponding author

Correspondence to Eamonn M M Quigley.

About this article

Publication history






Further reading